BridgeBio Oncology Therapeutics, Inc.(BBOT:US)
Market Cap$225.85M
Key Metrics
Price$2.82
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$154.1M
EBITDA (TTM)-$168.12M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$52.66M
Total Assets$417.65M
Net Assets$372.28M
Total Debt$2.64M
Key Metrics
Price$2.82
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$154.1M
EBITDA (TTM)-$168.12M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$52.66M
Total Assets$417.65M
Net Assets$372.28M
Total Debt$2.64M
Financials
| Name | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Cost of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - |
| $46.18M | $43.41M | $49.18M | $30.09M | $23.14M | $21.88M | $23.87M | $15.45M | |
| Research and Development | $39.8M | $38.07M | $35.05M | $27.44M | $20.64M | $19.54M | $22.51M | $13.17M |
| Selling, General, and Administrative | $6.38M | $5.33M | $14.13M | $2.66M | $2.5M | $2.34M | $1.36M | $2.28M |
| Other Operating Expenses | - | - | - | - | - | - | - | - |
Operating Income | -$46.18M | -$43.41M | -$49.18M | -$30.09M | -$23.14M | -$21.88M | -$23.87M | -$15.45M |
| $4.07M | $4.61M | $4.42M | $1.66M | $1.08M | $2.19M | $2.05M | $7K | |
| Non-Operating Interest Income | $3.94M | $4.42M | $3.44M | $1.67M | $1.81M | $2.13M | $1.77M | $5K |
| Non-Operating Interest Expense | - | - | - | - | - | - | - | - |
| Other Income/Expense | $129K | $187K | $980K | -$8K | -$727K | $59K | $282K | $2K |
Income Before Tax | -$42.11M | -$38.8M | -$44.76M | -$28.44M | -$22.06M | -$19.69M | -$21.82M | -$15.44M |
Income Tax | - | - | - | - | - | - | - | - |
Net Income | -$42.11M | -$38.8M | -$44.76M | -$28.44M | -$22.06M | -$19.69M | -$21.82M | -$15.44M |
Minority Interests | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - |
Net Income to Common | -$42.11M | -$38.8M | -$44.76M | -$28.44M | -$22.06M | -$19.69M | -$21.82M | -$15.44M |
Shares Outstanding (Basic) | 80.03M | 79.99M | 43.49M | 79.2M | 79.2M | - | 79.2M | 69.99M |
Shares Outstanding (Diluted) | 80.03M | 79.99M | 43.49M | 79.2M | 79.2M | - | 79.2M | 69.99M |
EPS (Basic) | -$526.11 | -$0.49 | -$1.03 | -$0.36 | -$0.28 | - | -$0.28 | -$0.22 |
EPS (Diluted) | -$526.11 | -$0.49 | -$1.03 | -$0.36 | -$0.28 | - | -$0.28 | -$0.22 |
EBIT | -$46.18M | -$43.41M | -$49.18M | -$30.09M | -$23.14M | -$21.88M | -$23.87M | -$15.45M |
EBITDA | -$45.99M | -$43.21M | -$49M | -$29.91M | -$23.08M | -$21.83M | -$23.82M | -$15.4M |